Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Pancreatic Cancer Resectable 1Ovarian Carcinosarcoma 1Neoplasms 1Liver Neoplasms 1Immune-related Adverse Event 1Esophageal Neoplasms 1Early Hormone Receptor-positive Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

pembrolizumab 16Radiotherapy 15Drug Therapy 14Paclitaxel 13Cisplatin 12Carboplatin 10Immunotherapy 9Esophagectomy 9Radiation 8Fluorouracil 8Surgical Procedures, Operative 7Capecitabine 7Blood Specimen Collection 7Oxaliplatin 6Nivolumab 6Immune Checkpoint Inhibitors 6Chemoradiotherapy 6nimotuzumab 5Trastuzumab 5130-nm albumin-bound paclitaxel 5sintilimab 4camrelizumab 4Leucovorin 4trastuzumab deruxtecan 3tislelizumab 3patritumab deruxtecan 3Surveys and Questionnaires 3Endoscopy 3Bevacizumab 3toripalimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Esophageal Neoplasms × Antineoplastic Agents × Clear all
NCT04688801 2022-11-16

Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer

The Second Hospital of Shandong University

Phase NA Recruiting
200 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡